NCT02667587: A reported trial by Bristol-Myers Squibb
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02667587 |
|---|---|
| Title | A Randomized Phase 3 Single Blind Study of Temozolomide Plus Radiation Therapy Combined With Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | May 9, 2016 |
| Completion date | Dec. 22, 2020 |
| Required reporting date | Dec. 22, 2021, midnight |
| Actual reporting date | Nov. 30, 2021 |
| Date last checked at ClinicalTrials.gov | April 27, 2026 |
| Days late | None |